The first of hundreds of lawsuits filed by consumers who claim the Abilify antipsychotic caused compulsive behavior has been scheduled for trial in June after a federal judge tossed a bid by drug makers to dismiss the litigation.

The bellwether trial would be the first to put a sustained spotlight on the extent to which the widely used medication has caused patients to succumb to uncontrollable urges to engage in impulsive gambling, shopping, eating, or sex. About 700 lawsuits have been filed in federal court in Florida and dozens more were filed in other states, mostly in New Jersey.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy